Imagion Biosystems (IBX) Stock Price, News & Analysis

Company Overview

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 10.77 million shs
• Average Volume: N/A
• Market Capitalization: A$3.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IBX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Imagion Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Imagion Biosystems investors own include EMCORE (EMKR), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and VelocityShares 1x Long VSTOXX Futures ETN (EVIX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:IBX
• CIK: N/A
• Web: www.imagionbiosystems.com
• Phone: 855-564-5264
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$6.32 million
• Net Margins: -265.26%
• Pretax Margin: N/A
• Return on Equity: 139.43%
• Return on Assets: -109.93%

Debt

• Debt-to-Equity Ratio: -60.49
• Current Ratio: 0.09
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: A$5.92 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.00
• Book Value: A($0.16) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,650,000
• Free Float: N/A
• Market Cap: A$3.62 million
• Optionable: Not Optionable
• Beta: 2.05